Compare CC & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CC | RAPP |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2014 | 2024 |
| Metric | CC | RAPP |
|---|---|---|
| Price | $14.33 | $40.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $20.11 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 1.6M | 263.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,638,000,000.00 | N/A |
| Revenue This Year | $6.15 | N/A |
| Revenue Next Year | $5.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $10.44 | $23.75 |
| 52 Week High | $28.67 | $52.93 |
| Indicator | CC | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 33.60 |
| Support Level | $11.55 | $38.95 |
| Resistance Level | $16.37 | $43.99 |
| Average True Range (ATR) | 0.51 | 1.96 |
| MACD | -0.04 | -0.88 |
| Stochastic Oscillator | 14.02 | 3.81 |
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.